

MILESTONES

NIH/NCI
 First human trials of a preventive human papillomavirus cervical cancer vaccine (HPV 16). This virus-like particle (VLP) vaccine was the progenitor of the HPV vaccine (Gardasil) recently licensed by the FDA, & of a second vaccine (Cervarix).
1 • **1997-2001**

1998-2003 • **VaxGen, Inc.**
 Lead clinical trial site in first phase III HIV vaccine trial.
2

NIH/NIAID
 Lead clinical trial site for first human studies of live attenuated recombinant RSV vaccines.
3 • **1998-2003**

1998-2003 • **Avant/Microscience**
 Leading single dose, oral cholera (Peru-15) & typhoid vaccines (MICRO-TY/ZH9) shown to be safe & immunogenic in early Phase I/II trials performed in Baltimore & Vermont (typhoid only).
4

SBL Vaccines
 Established efficacy of whole cell ETEC vaccine in field trials in Guatemala & Mexico.
5 • **1998-2002**

1999-2003 • **Salix**
 Multicenter clinical trials that led to licensure of Rifamixin for treatment of traveler's diarrhea.
6

NIH/NIAID
 First human trial of a recombinant dengue virus vaccine; additional trials are ongoing.
7 • **1999-2006**

2000-2002 • **Intellivax**
 First human trial of intranasal Shigella vaccine demonstrated short-term protection against Shigella flexneri in an experimental challenge model.
8

NIH/DAIDS/HVTN & AlphaVax, Inc.
 Lead clinical trial site for 1st human study of HIV vaccine using Venezuelan Equine Encephalitis vector.
9 • **2000-2005**

2000-2005 • **Acambis/IOMAI**
 Challenge studies evaluating ETEC vaccines demonstrated that anti-CS3 serum IgA titer is a marker for protection against strains sharing this colonization factor.
10

Merck & Co.
 Lead site for the first human testing of a live-attenuated adenovirus vectored HIV vaccine.
11 • **2001-2006**

2002 • **NIH/NIAID**
 First human trial of malaria transmission blocking vaccine.
12

MILESTONES

NIH/NIAID
Pre-clinical study finds that immune complexes play a role in enhanced RSV disease.

13

• **2002**

2004-2006

VaxGen
New recombinant anthrax vaccine (rPA-102) shown to be safe & immunogenic in multi-center trials carried out in Baltimore & other U.S. cities.

14

IOMAI
First human trial to evaluate the protective efficacy of an ETEC vaccine delivered transcutaneously by an arm patch.

15

• **2004-2006**

2005-2006

Merck & Co.
Lead clinical trial site for first human studies of a preventive S. aureus vaccine.

16

NIH/NIAID
First human trials of a live attenuated West Nile virus vaccine.

17

• **2005-2006**

2005-2006

NIH/NIAID & MedImmune
First human trials of a live attenuated H9N2 A/AA ca avian influenza virus vaccine.

18

NIH/NIAID & MedImmune
First human trials of a live attenuated H5N1 A/AA ca avian influenza virus vaccine.

19

• **2006**

2006-2007

IOMAI
Phase II field study finds an ETEC vaccine delivered transcutaneously by arm patch protects travelers to Guatemala and Mexico.

20

PATH/EVI
Developed and validated low-inoculum ETEC challenge model in human volunteers that enabled 2 log reduction in challenge strain while maintaining consistently high attack rates.

21

• **2009**

2009

CSL Limited
Principal Investigators and lead site in a large multicenter trial of a pandemic H1N1 influenza vaccine.

22

Norovirus Vaccine Against Experimental Human Norwalk Virus Illness
This norovirus VLP vaccine provides protection against illness and infection after challenge with a homologous virus.

23

• **2011**

2012

ACIP Appointment
Dr. Ruth Karron was appointed to the Advisory Committee on Immunization Practices.

24

MILESTONES

NIH-developed candidate dengue vaccine (TV003) shows promise in early-stage trial

25

2013

2013

26

PATH Vaccine Development Program - Shigella vaccine trial

World Vaccine Congress Winner

Dr. Anna P. Durbin is the World Vaccine Congress 2014 winner for "Best Academic Research Team"

27

2014

2020

28

Pfizer mRNA COVID-19 vaccine trial begins

Dr. Kawsar Talaat is CIR site PI in this multi-site phase III trial that led to one of the first licensed COVID-19 vaccines

Astra-Zeneca COVID-19 vaccine trial begins

Dr. Anna Durbin is CIR site PI in this multi-site phase II trial to test a single dose COVID-19 vaccine

29

2020

MILESTONE NO. 6

MILESTONE NO. 7

MILESTONE NO. 12

Lorem ipsum Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed diam.